nach oben

Erschienen in:

01.03.2008 | Original Paper

Initiation, Adherence, and Retention in a Randomized Controlled Trial of Directly Administered Antiretroviral Therapy

verfasst von: Duncan Smith-Rohrberg Maru, R. Douglas Bruce, Mary Walton, Jo Anne Mezger, Sandra A. Springer, David Shield, Frederick L. Altice

Erschienen in: AIDS and Behavior | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Directly administered antiretroviral therapy (DAART) can improve health outcomes among HIV-infected drug users. An understanding of the utilization of DAART—initiation, adherence, and retention—is critical to successful program design. Here, we use the Behavioral Model to assess the enabling, predisposing, and need factors impacting adherence in our randomized, controlled trial of DAART versus self-administered therapy (SAT) among 141 HIV-infected drug users. Of 88 participants randomized to DAART, 74 (84%) initiated treatment, and 51 (69%) of those who initiated were retained in the program throughout the entire six-month period. Mean adherence to directly observed visits was 73%, and the mean overall composite adherence score was 77%. These results were seen despite the finding that 75% of participants indicated that they would prefer to take their own medications. Major causes of DAART discontinuation included hospitalization, incarceration, and entry into drug-treatment programs. The presence of depression and the lack of willingness to travel greater than four blocks to receive DAART predicted time-to-discontinuation.

Altice, F. L., & Friedland, G. H. (1998). The era of adherence to HIV therapy. Annals of Internal Medicine, 129, 503–505.PubMed

Altice, F. L., Mezger, J. A., Hodges, J., Bruce, R. D., Marinovich, A., Walton, M., Springer, S., & Friedland, G. H. (2004). Developing a directly administered antiretroviral therapy intervention for HIV infected drug users: implications for program replication. Clinical Infectious Diseases, 38, S376–S387.PubMedCrossRef

Altice, F. L., Mostashari, F., & Friedland, G. H. (2001). Trust and the acceptance of and adherence to antiretroviral therapy. Journal of the Acquired Immune Deficiency Syndromes (1999), 28, 47–58.

Altice, F. L., Smith-Rohrberg, D., Bruce, R. D., Springer, S. A., & Friedland, G. H. (2007). Superiority of directly administered antiretroviral therapy compared to self-administered therapy among HIV-infected drug users: A randomized, controlled trial. Clinical Infectious Diseases, 45, 770–778.PubMedCrossRef

Altice, F. L., Springer, S., Buitrago, M., Hunt, D. P., & Friedland, G. H. (2003). Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. Journal of Urban Health, 80, 416–427.PubMed

Andersen, R. M. (1995). Revisiting the behavioral model and access to medical care: Does it matter? Journal of Health and Social Behavior, 36, 1–10.PubMedCrossRef

Andersen, R., & Aday, L. A. (1978). Access to medical care in the U.S.: Realized and potential. Medical Care, 16, 533–546.PubMedCrossRef

Arnsten, J. H., Breg, K. M., Cooperman, N. A., Vinnanueva, M., Li, X., & Parker, F. (2007). A 6-month randomized controlled trial of directly observed therapy delivered in methadone clinics. Paper presented at the proceedings of the 2nd NIMH/IAPAC international conference on HIV treatment adherence, Jersey City, NJ.

Arnsten, J. H., Demas, P. A., Farzadegan, H., Grant, R. W., Gourevitch, M. N., Chang, C. J., et al. (2001). Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. Clinical Infectious Diseases, 33(8), 1417–1423.PubMedCrossRef

Arnsten, J. H., Demas, P. A., Grant, R. W., Gourevitch, M. N., Farzadegan, H., Howard, A. A., et al. (2002). Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. Journal of General Internal Medicine, 17, 377–381.PubMed

Behforouz, H. L., Kalmus, A., Scherz, C. S., Kahn, J. S., Kadakia, M. B., & Farmer, P. E. (2004). Directly observed therapy for HIV antiretroviral therapy in an urban US setting. Journal of the Acquired Immune Deficiency Syndromes, 36, 642–645.CrossRef

Carretero, M. D., Burgess, A. P., Soler, P., Soler, M., & Catalan, J. (1996). Reliability and validity of an HIV-specific health-related quality-of-life measure for use with injecting drug users. AIDS, 10, 1699–1705.PubMed

Conway, B., Prasad, J., Reynolds, R., Farley, J., Jones, M., Jutha, S., et al. (2004). Directly observed therapy for the management of HIV-infected patients in a methadone program. Clinical Infectious Diseases, 38, S402–S408.PubMedCrossRef

Dalessandro, M., Conti, C. M., Gambi, F., Falasca, K., Doyle, R., Conti, P., et al. (2007). Antidepressant therapy can improve adherence to antiretroviral regimens among HIV-infected and depressed patients. Journal of Clinical Psychopharmacology, 27, 58–61.PubMedCrossRef

Garland, W. H., Wohl, A. R., Valencia, R., Witt, M. D., Squires, K., Kovacs, A., et al. (2007). The acceptability of a directly-administered antiretroviral therapy (DAART) intervention among patients in public HIV clinics in Los Angeles, California. AIDS Care, 19, 159–167.PubMedCrossRef

Gelberg, L., Andersen, R. M., & Leake, B. D. (2000). The behavioral model for vulnerable populations: Application to medical care use and outcomes for homeless people. Health Services Research, 34, 1273–1302.PubMed

Greenberg, B., Berkman, A., Thomas, R., Hoos, D., Finkelstein, R., Astemborski, J., et al. (1999). Evaluating supervised HAART in late-stage HIV among drug users: A preliminary report. Journal of Urban Health, 76, 468–480.PubMedCrossRef

Kozal, M. J., Amico, K. R., Chiarella, J., Cornman, D., Fisher, W., Fisher, J., et al. (2005). HIV drug resistance and HIV transmission risk behaviors among active injection drug users. Journal of Acquired Immune Deficiency Syndromes, 40(1), 106–109.PubMedCrossRef

Lima, V. D., Geller, J., Bangsberg, D. R., Patterson, T. L., Daniel, M., Kerr, T., et al. (2007). The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS, 21(9), 1175–1183.PubMedCrossRef

Liu, H., Golin, C. E., Miller, L. G., Hays, R. D., Beck, C. K., Sanandaji, S., et al. (2001). A comparison study of multiple measures of adherence to HIV protease inhibitors. Annals of Internal Medicine, 134, 968–977.PubMed

Liu, H., Miller, L. G., Hays, R. D., Golin, C. E., Wu, T., Wenger, N. S., et al. (2006). Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. Journal of Acquired Immune Deficiency Syndromes, 41, 315–322.PubMedCrossRef

Lucas, G. M., Cheever, L. W., Chaisson, R. E., & Moore, R. D. (2001). Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes, 27, 251–259.PubMed

Lucas, G. M., Gebo, K. A., Chaisson, R. E., & Moore, R. D. (2002). Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS, 16(5), 767–774.PubMedCrossRef

Lucas, G. M., Griswold, M., Gebo, K. A., Keruly, J., Chaisson, R. E., & Moore, R. D. (2006a). Illicit drug use and HIV-1 disease progression: A longitudinal study in the era of highly active antiretroviral therapy. American Journal of Epidemiology, 163(5), 412–420.PubMedCrossRef

Lucas, G. M., Mullen, B. A., McCaul, M. E., Weidle, P. J., Hader, S., & Moore, R. D. (2007). Adherence, drug use, and treatment failure in a methadone-clinic-based program of directly administered antiretroviral therapy. AIDS Patient Care and STDs, 21(8), 564–574.PubMedCrossRef

Lucas, G. M., Mullen, B. A., Weidle, P. J., Hader, S., McCaul, M. E., & Moore, R. D. (2006b). Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clinical Infectious Diseases, 42(11), 1628–1635.PubMedCrossRef

Lucas, G. M., Weidle, P. J., Hader, S., & Moore, R. D. (2004). Directly administered antiretroviral therapy in an urban methadone maintenance clinic: A nonrandomized comparative study. Clinical Infectious Diseases, 38, S409–S413.PubMedCrossRef

Macalino, G. E., Hogan, J. W., Mitty, J. A., Bazerman, L. B., Delong, A. K., Loewenthal, H., et al. (2007). A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users. AIDS, 21, 1473–1477.PubMedCrossRef

Macalino, G. E., Mitty, J. A., Bazerman, L. B., Singh, K., McKenzie, M., & Flanigan, T. (2004). Modified directly observed therapy for the treatment of HIV-seropositive substance users: lessons learned from a pilot study. Clinical Infectious Diseases, 38, S393–S397.PubMedCrossRef

Maru, D. S. R., Kozal, M. J., Bruce, R. D., Springer, S. A., & Altice, F. L. (2007). Directly administered antiretroviral therapy for HIV-infected drug users does not impact antiretroviral resistance: results from a randomized, controlled trial. Journal of the Acquired Immune Deficiency Syndromes, 46(5), 555–563.CrossRef

Mitchell, C. G., Freels, S., Creticos, C. M., Oltean, A., & Douglas, R. (2007). Preliminary findings of an intervention integrating modified directly observed therapy and risk reduction counseling. AIDS Care, 19(4), 561–564.

Mitty, J. A., Macalino, G. E., Bazerman, L. B., Loewenthal, H. G., Hogan, J. W., MacLeod, C. J., et al. (2005). The use of community-based modified directly observed therapy for the treatment of HIV-infected persons. Journal of Acquired Immune Deficiency Syndromes, 39, 545–550.PubMed

Murri, R., Fantoni, M., Del Borgo, C., Izzi, I., Visona, R., Suter, F., et al. (1999). Intravenous drug use, relationship with providers, and stage of HIV disease influence the prescription rates of protease inhibitors. Journal of Acquired Immune Deficiency Syndromes, 22, 461–466.PubMed

Paterson, D. L., Potoski, B., & Capitano, B. (2002). Measurement of adherence to antiretroviral medications. Journal of Acquired Immune Deficiency Syndromes, 31, S103–S106.PubMed

Rockwell, R., Des Jarlais, D. C., Friedman, S. R., Perlis, T. E., & Paone, D. (1999). Geographic proximity, policy and utilization of syringe exchange programmes. AIDS Care, 11, 437–442.PubMedCrossRef

Santos, C. Q., Adeyemi, O., & Tenorio, A. R. (2006). Attitudes toward directly administered antiretroviral therapy (DAART) among HIV-positive inpatients in an inner city public hospital. AIDS Care, 18, 808–811.PubMedCrossRef

Smith-Rohrberg, D., & Altice, F. L. (2006). Randomized, controlled trials of directly administered antiretroviral therapy for HIV-infected patients: Questions about study population and analytical approach. Clinical Infectious Diseases, 43, 1221–1222.PubMedCrossRef

Smith-Rohrberg, D., Mezger, J., Walton, M., Bruce, R. D., & Altice, F. L. (2006). Impact of enhanced services on virologic outcomes in a directly administered antiretroviral therapy trial for HIV-infected drug users. Journal of Acquired Immune Deficiency Syndromes, 43, S48–S53.PubMedCrossRef

Tinoco, I., Giron-Gonzalez, J. A., Gonzalez-Gonzalez, M. T., Vergara de Campos, A., Rodriguez-Felix, L., Serrano, A., et al. (2004). Efficacy of directly observed treatment of HIV infection: Experience in AIDS welfare homes. European Journal of Clinical Microbiology and Infectious Diseases, 23, 331–335.CrossRef

Tyndall, M., McNally, M., Lai, C., Zhang, R., Wood, E., Kerr, T., et al. (2007). Directly observed therapy programs for antiretroviral treatment among injection drug users in Vancouver: Access, adherence and outcomes. International Journal of Drug Policy, 18(4), 281–287.

Visnegarwala, F., Rodriguez-Barradass, M. C., Graviss, E. A., Caprio, M., Nykyforchyn, M., & Laufman, L. (2006). Community outreach with weekly delivery of anti-retroviral drugs compared to cognitive-behavioural health care team-based approach to improve adherence among indigent women newly starting HAART. AIDS Care, 18, 332–338.PubMedCrossRef

Wohl, A. R., Garland, W. H., Valencia, R., Squires, K., Witt, M. D., Kovacs, A., et al. (2006). A randomized trial of directly administered antiretroviral therapy and adherence case management intervention. Clinical Infectious Diseases, 42, 1619–1627.PubMedCrossRef

Wu, A. W. (1999). MOS-HIV health survey: Users manual. John Hopkins University.

Wu, A. W., Revicki, D. A., Jacobson, D., & Malitz, F. E. (1997). Evidence for reliability, validity and usefulness of the medical outcomes study HIV health survey (MOS-HIV). Quality of Life Research, 6, 481–493.PubMedCrossRef

Titel: Initiation, Adherence, and Retention in a Randomized Controlled Trial of Directly Administered Antiretroviral Therapy
verfasst von: Duncan Smith-Rohrberg Maru
R. Douglas Bruce
Mary Walton
Jo Anne Mezger
Sandra A. Springer
David Shield
Frederick L. Altice
Publikationsdatum: 01.03.2008
Verlag: Springer US
Erschienen in: AIDS and Behavior / Ausgabe 2/2008
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-007-9336-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2008

Assessing Microbicide Acceptability: A Comprehensive and Integrated Approach

Stigma, Secrecy, and Discrimination: Ethnic/Racial Differences in the Concerns of People Living with HIV/AIDS

The Effectiveness of Respondent Driven Sampling for Recruiting Males Who have Sex with Males in Dhaka, Bangladesh

Social, Behavioural, and Intervention Research among People of Sub-Saharan African Origin Living with HIV in the UK and Europe: Literature Review and Recommendations for Intervention

The Cognitive Escape Scale: Measuring HIV-related Thought Avoidance

Immigration Status and HIV-risk Related Behaviors among Female Sex Workers in South America